Developing country vaccine industry

Nearly half of Gavi vaccine suppliers are based in emerging markets

Each strategic period has seen more Gavi-funded doses of World Health Organization (WHO)-prequalified vaccines supplied by manufacturers of the Developing Countries Vaccine Manufacturers Network (DCVMN). The number and choice of vaccine product presentations has increased; the Gavi supplier base has diversified; and competition has increased overall. This has often resulted in reduced prices.

Through Gavi’s market shaping efforts, the number of manufacturers supplying prequalified Gavi-supported vaccines reached 20 in 2024 (with nearly half based in low- and middle-income countries) – compared with 5 in 2001.

The Vaccine Alliance has assigned a seat on its Board to a representative of the Developing Countries Vaccine Manufacturers Network (DCVMN), a voluntary alliance of over 40 vaccine manufacturers from 15 developing countries.

Industrialised country vaccine industry

Vaccine manufacturers based in higher-income countries ensure affordable prices for lower-income countries

Gavi’s market shaping efforts with vaccine manufacturers in higher-income countries make vaccines and other immunisation products more accessible and affordable for lower-income countries.

Representatives of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) have one seat on the Gavi Board. IFPMA represents the innovative pharmaceutical industry at the international level and in official relations with the United Nations.

Building on their engagement in the Children's Vaccine Initiative launched in 1990, IFPMA members have worked in partnership with Gavi since its launch in 2000, supplying vaccines to a number of key Gavi-supported vaccine programmes.

African Vaccine Manufacturing Accelerator (AVMA)

In June 2024, Gavi launched the African Vaccine Manufacturing Accelerator (AVMA) to accelerate the expansion of commercially viable vaccine manufacturing in Africa. This billion-dollar, ten-year financing mechanism offers a ‘pull financing mechanism’ by providing downstream incentives to manufacturers to help offset initial costs of development and production. Designed to complement efforts being led by the Africa Centres for Disease Control and Prevention (Africa CDC), the African Union and other partners, AVMA leverages Gavi’s role as one of the world’s largest purchasers of vaccines and more than two decades of the Vaccine Alliance’s expertise in shaping vaccine markets.

With sustained political commitment, and scheduled operational refinement, AVMA remains in position to support a self-sufficient, globally competitive African vaccine manufacturing sector that enhances both continental and global health security. Gavi will continue to leverage the unique power of the Alliance, working with partners to address key outstanding challenges of regulatory capacity, early access to finance and demand predictability.